2126134-01-6

CCT365623 is a Lysyl oxidase inhibitor. CCT365623 disrupts EGFR cell surface retention and delays the growth of primary and metastatic tumour cells in vivo. LOX regulates EGFR cell surface retention to drive tumour progression.

CCT365623 is a potent and orally active LOX inhibitor with an IC50 of 0.9 μM. CCT365623 has potent anti-metastatic efficacy in vivo[1].